Keay Nakae
Stock Analyst at Chardan Capital
(4.47)
# 318
Out of 5,111 analysts
252
Total ratings
46.91%
Success rate
28.69%
Average return
Main Sectors:
Stocks Rated by Keay Nakae
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DYN Dyne Therapeutics | Maintains: Buy | $38 | $19.59 | +93.98% | 14 | Dec 9, 2025 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $60 | $68.45 | -12.34% | 22 | Dec 1, 2025 | |
| ALUR Allurion Technologies | Maintains: Neutral | $2.5 | $1.52 | +64.47% | 7 | Nov 20, 2025 | |
| SABS SAB Biotherapeutics | Maintains: Buy | $12 | $4.00 | +200.00% | 18 | Nov 17, 2025 | |
| ABUS Arbutus Biopharma | Maintains: Buy | $5 | $4.95 | +1.01% | 14 | Nov 14, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $14 | $5.91 | +136.89% | 22 | Nov 14, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $100 | $75.12 | +33.12% | 6 | Nov 13, 2025 | |
| OBIO Orchestra BioMed Holdings | Maintains: Buy | $20 | $4.30 | +365.12% | 13 | Nov 13, 2025 | |
| KRRO Korro Bio | Downgrades: Neutral | $25 → $7 | $7.96 | -12.06% | 4 | Nov 13, 2025 | |
| RNA Avidity Biosciences | Maintains: Neutral | $72 | $71.86 | +0.19% | 21 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $2.45 | +63.27% | 16 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $6.60 | +430.30% | 13 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $325 → $400 | $391.50 | +2.17% | 14 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 | $1.83 | +173.22% | 5 | Jun 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $1.25 → $6 | $15.90 | -62.26% | 10 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $6 | $3.95 | +51.90% | 7 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $8 | $0.87 | +822.40% | 10 | Nov 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.05 | - | 5 | Feb 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $6 | $17.71 | -66.12% | 7 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $1,140 → $380 | $1.73 | +21,865.32% | 4 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $65 → $55 | $12.33 | +346.07% | 10 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $1.25 → $10 | $5.73 | +74.52% | 5 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $100 → $88 | $21.96 | +298.45% | 2 | Sep 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $0.7 → $13 | $1.38 | +842.03% | 3 | Feb 9, 2021 |
Dyne Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $38
Current: $19.59
Upside: +93.98%
Arrowhead Pharmaceuticals
Dec 1, 2025
Maintains: Buy
Price Target: $60
Current: $68.45
Upside: -12.34%
Allurion Technologies
Nov 20, 2025
Maintains: Neutral
Price Target: $2.5
Current: $1.52
Upside: +64.47%
SAB Biotherapeutics
Nov 17, 2025
Maintains: Buy
Price Target: $12
Current: $4.00
Upside: +200.00%
Arbutus Biopharma
Nov 14, 2025
Maintains: Buy
Price Target: $5
Current: $4.95
Upside: +1.01%
Coya Therapeutics
Nov 14, 2025
Maintains: Buy
Price Target: $14
Current: $5.91
Upside: +136.89%
Monopar Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $100
Current: $75.12
Upside: +33.12%
Orchestra BioMed Holdings
Nov 13, 2025
Maintains: Buy
Price Target: $20
Current: $4.30
Upside: +365.12%
Korro Bio
Nov 13, 2025
Downgrades: Neutral
Price Target: $25 → $7
Current: $7.96
Upside: -12.06%
Avidity Biosciences
Nov 11, 2025
Maintains: Neutral
Price Target: $72
Current: $71.86
Upside: +0.19%
Nov 4, 2025
Maintains: Buy
Price Target: $4
Current: $2.45
Upside: +63.27%
Aug 8, 2025
Maintains: Buy
Price Target: $35
Current: $6.60
Upside: +430.30%
Aug 1, 2025
Maintains: Buy
Price Target: $325 → $400
Current: $391.50
Upside: +2.17%
Jun 25, 2025
Maintains: Buy
Price Target: $5
Current: $1.83
Upside: +173.22%
May 8, 2025
Downgrades: Neutral
Price Target: $1.25 → $6
Current: $15.90
Upside: -62.26%
Mar 28, 2025
Maintains: Buy
Price Target: $6
Current: $3.95
Upside: +51.90%
Nov 13, 2024
Maintains: Buy
Price Target: $10 → $8
Current: $0.87
Upside: +822.40%
Feb 9, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.05
Upside: -
Aug 4, 2023
Maintains: Sell
Price Target: $8 → $6
Current: $17.71
Upside: -66.12%
Nov 10, 2022
Maintains: Buy
Price Target: $1,140 → $380
Current: $1.73
Upside: +21,865.32%
Nov 9, 2022
Maintains: Buy
Price Target: $65 → $55
Current: $12.33
Upside: +346.07%
Aug 16, 2022
Maintains: Neutral
Price Target: $1.25 → $10
Current: $5.73
Upside: +74.52%
Sep 20, 2021
Upgrades: Neutral
Price Target: $100 → $88
Current: $21.96
Upside: +298.45%
Feb 9, 2021
Downgrades: Neutral
Price Target: $0.7 → $13
Current: $1.38
Upside: +842.03%